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We investigated the direct effect of hepatocyte growth factor (HGF) on the expression of type I collagen in normal
and scleroderma dermal ﬁbroblasts, and analyzed the mechanisms underlying the effect in vitro. HGF did not
change the protein expression of type I procollagen in the medium of normal human ﬁbroblasts, whereas it reduced
the expression in scleroderma ﬁbroblasts. But mRNA levels and the promoter activity of a2(I) collagen gene were
not significantly affected by HGF in either of the cells. On the other hand, matrix metalloproteinase-1 expression or
activity was increased by HGF in both cells, but HGF had stronger effects in scleroderma ﬁbroblasts than normal
ﬁbroblasts. Scleroderma ﬁbroblasts overexpressed c-met protein, the receptor for HGF. The overexpression in
scleroderma ﬁbroblasts was abolished by the addition of antisense transforming growth factor (TGF)-b1 oligonuc-
leotide. Our study indicated that HGF may reduce type I collagen accumulation only in scleroderma ﬁbroblasts by
enhancing collagenolysis activity, probably because of the overexpression of c-met because of autocrine TGF-b
signaling. Thus, further investigation of the effects of HGF on collagen metabolism may contribute to the treatment
of ﬁbrosis in scleroderma.
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Hepatocyte growth factor (HGF), originally identified as a
potent mitogen for hepatocytes and also known as a ‘‘scat-
ter factor’’, is a multifunctional mediator that shows mi-
togenic and morphogenetic activities in a variety of cells
(Nakamura et al, 1984; Stoker et al, 1987; Gohda et al, 1988;
Nakamura et al, 1989; Zarnegar and Michalopoulos, 1989;
Weidner et al, 1991; Boros and Miller, 1995). C-met is
known as a tyrosine kinase receptor of HGF, which is a
heterodimeric receptor consisting of an extracellular a-sub-
unit (p50 a met) and a transmembrane b-subunit (p 145 b
met). C-met is usually expressed in epithelial cells including
hepatocytes, keratinocytes, or melanocytes, but its expres-
sion is reduced in mesenchymal cells such as fibroblasts.
Recently, HGF has been shown to reverse fibrogenic
processes including hepatic fibrosis (Matusuda et al, 1995;
Yasuda et al, 1996; Matsuda et al, 1997; Ueki et al, 1999). In
these reports, HGF inhibited extracellular matrix deposition
and successfully reduced the amount of pre-existing extra-
cellular matrix constituents including fibrillar collagens.
Most of these reports demonstrated the effects of HGF on
tissue fibrosis in an animal model, but its effects on normal
human cells in vitro are poorly investigated. Thus, the
mechanism by which HGF acts against fibrogenesis is not
fully understood. One of the anti-fibrogenic effects of HGF,
however, is thought to be expressed by the induction of
matrix metalloproteinases (MMP) (Matusuda et al, 1995;
Matsuda et al, 1997; Ueki et al, 1999). Notably, MMP-1, a
collagenase that mainly digests interstitial collagens types I
and III, is reported to be upregulated by HGF in several cell
types (Brummer et al, 2002; Ozaki et al, 2002).
Systemic sclerosis (SSc) or scleroderma is an acquired
disorder that typically results in fibrosis of the skin and in-
ternal organs (LeRoy et al, 1988). In SSc, fibroblast activa-
tion and disturbed interactions with different components of
the extracellular matrix resulting from inflammation, auto-
immune attack, and vascular damage have been implicated
to play a central role in dermal fibrosis (Korn, 1989; Mauch
and Krieg, 1990). The autocrine transforming growth factor
(TGF)-b signaling is thought to be involved in this fibroblast
activation or extracellular matrix interaction (Border and
Noble, 1994; Kawakami et al, 1998; Varga, 2002).
Fibroblasts from affected SSc skin cultured in vitro pro-
duce excessive amounts of various collagens, mainly types
I and III collagens (LeRoy, 1974; Jimenez et al, 1986), and
display increased transcriptional activities of the corre-
sponding genes (Kikuchi et al, 1992; Hitraya and Jimenez,
1996). On the other hand, the basal protein expression of
MMP-1 is reduced in SSc fibroblasts compared with fibro-
blasts of normal subjects (NS) (Takeda et al, 1994; Kuroda
and Shinkai, 1997). Thus, the induction of MMP-1 may be
a reliable approach to the treatment of SSc. But al-
though immunocytochemical staining revealed that c-met
Abbreviations: CAT, chloramphenicol acetyltransferase; HGF, he-
patocyte growth factor; MEM, modified Eagle’s medium; MMP,
matrix metalloproteinase; NS, normal subjects; SSc, systemic
sclerosis; TGF, transforming growth factor; TIMP, tissue inhibitor of
metalloproteinase
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is spontaneously overexpressed in SSc fibroblasts (Kawa-
guchi et al, 2002), the effects of HGF on SSc dermal
fibroblasts have hardly been investigated.
In this study, we investigated the direct effect of HGF on
the expression of type I collagen from cultured human der-
mal fibroblasts. We demonstrated that HGF has different
effects on protein expression of type I procollagen in NS
and SSc dermal fibroblasts, and analyzed the mechanisms
underlying these effects.
Results
HGF effect on protein and mRNA expression of type I
collagen First, we examined the concentration dependen-
cy of HGF effect on the expression of type I procollagen
protein in NS and SSc fibroblasts. The levels of type I pro-
collagen protein in the media of NS fibroblasts were un-
changed by the stimulation with HGF for 72 h (Fig 1A). On
the other hand, they were reduced by HGF in a concentra-
tion-dependent manner after 72 h in SSc fibroblasts.
Next, to determine whether the HGF-mediated type I
procollagen protein downregulation in SSc fibroblasts is
correlated with the decrease of mRNA, human dermal fib-
roblasts were incubated in the presence or absence of 10
ng per mL of HGF under the same conditions, and mRNA
expression was analyzed by northern blotting. The expres-
sion levels of a2(I) collagen mRNA were slightly elevated
after stimulation with HGF in both NS and SSc fibroblasts
but these effects were minimum and not significant (Fig 1B).
To confirm this result, we investigated the transcriptional
activity of the human a2(I) collagen gene. On treatment with
10 ng per mL of HGF, a2(I) collagen promoter activity was
not significantly elevated in NS or SSc fibroblasts (Fig S1).
Thus, the effect of HGF on the type I collagen protein level in
the medium did not parallel that on the mRNA level or pro-
moter activation in SSc fibroblasts. These results suggest
that HGF is essentially not a downregulator of type I pro-
collagen expression in NS and SSc fibroblasts, and the
higher extracellular collagenolysis activation by HGF in SSc
fibroblasts may cause the reduction of type I collagen ex-
pression in the medium.
Effects of HGF on the expression of MMP-1 protein or
mRNA in NS and SSc dermal ﬁbroblasts To determine
which fibrogenic/fibrolytic protein contributes to the colla-
genolysis activation by HGF in SSc fibroblasts, we exam-
ined the time-dependent effect of HGF on the protein level
of MMP-1, tissue inhibitor of metalloproteinase (TIMP-1), or
TIMP-2. MMP-1 protein levels were elevated after 24 h and
markedly increased after 72 h in both NS and SSc fibro-
blasts compared with the levels in untreated cells (Fig 2A).
On the other hand, the accumulation of TIMP protein in the
medium was not increased by HGF compared with the lev-
els in control cells. Next, we investigated the concentration
dependency of the effect of HGF on the expression of
MMP-1. MMP-1 protein expression was upregulated by the
treatment with 10 ng per mL of HGF significantly in both NS
and SSc fibroblasts (2.5- and 6.1-fold, respectively) (Fig S2).
MMP-1 mRNA expression was also elevated after stimula-
tion with HGF for 6 h, and sustained until 48 h later, espe-
cially in SSc fibroblasts (Fig S3). Furthermore, we
investigated the transcriptional activity of the human
MMP-1 gene to determine whether HGF induces MMP-1
mRNA expression at the transcriptional level. On treatment
with 10 ng per mL of HGF, MMP-1 promoter activity was
Figure1
Expression of type I procollagen protein in the medium by he-
patocyte growth factor (HGF) in normal subjects (NS) and systemic
sclerosis (SSc) fibroblasts. (A) For the examination of the concentra-
tion dependency of the HGF effect, cells were incubated in serum-free
medium for 72 h in the presence or absence of HGF at the indicated
doses prior to collection of the medium in NS and SSc fibroblasts.
Conditioned media and cell lysates (normalized for protein concentra-
tions as measured with the Bio-Rad reagent) were subjected to
immunoblotting with anti-type I collagen antibody and anti-b-actin an-
tibody, respectively. One representative of independent experiments in
five NS and five SSc fibroblasts is shown. Type I procollagen protein
levels quantitated by scanning densitometry and corrected for the lev-
els of b-actin in the same samples are shown relative to those in NS
(open bars) or SSc (closed bars) fibroblasts without HGF stimulation
(100 arbitrary units (AU)). Data are expressed as the mean  SD of
independent experiments in each fibroblast. po0.05 as compared
with the value in untreated cells. (B) Cultured fibroblasts were incubat-
ed in the presence or absence of 10 ng per mL of HGF under the same
conditions for the indicated time courses, and northern blot analysis of
a2(I) collagen mRNA expression was performed in NS and SSc fibro-
blasts. Levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
mRNA are shown as a loading control. One representative of inde-
pendent experiments in five NS and five SSc fibroblasts is shown. a2(I)
collagen mRNA levels quantitated by scanning densitometry and cor-
rected for the levels of GAPDH in the same samples are shown relative
to those in NS (open bars) or SSc (closed bars) fibroblasts without HGF
stimulation (100 AU). Data are expressed as the mean  SD of inde-
pendent experiments in each fibroblast.
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elevated maximally in NS fibroblasts (2.2-fold) to the same
extent as the level of protein or mRNA induction. On the
other hand, the fold induction of MMP-1 promoter activity
by HGF (7.4-fold) in SSc fibroblasts remarkably overcame
that in NS fibroblasts (Fig S4).
We compared the expression of MMP-1 protein following
stimulation with HGF between NS and SSc fibroblasts. The
basal protein expression of MMP-1 was decreased in SSc
fibroblasts compared with NS fibroblasts as reported pre-
viously (Takeda et al, 1994; Kuroda and Shinkai, 1997),
whereas the HGF-treated MMP-1 level in SSc fibroblasts
was overexpressed more dramatically than in NS fibroblasts
(Fig 2B). Furthermore, specific ELISA revealed that HGF
also increased MMP-1 catalytic activity more apparently in
the cultured medium of SSc fibroblasts than in that of nor-
mal fibroblasts (Fig S5).
Taken together, these results indicate that HGF induces
MMP-1 expression and activity in both NS and SSc fibro-
blasts, but that there is quite a difference in the reactivity of
MMP-1 expression and activity to HGF between these cells.
This difference may cause the difference in the effect of
HGF on the expression of type I procollagen protein be-
tween NS and SSc fibroblasts.
Comparison of c-met expression levels between NS
and SSc dermal ﬁbroblasts As mentioned above, immuno-
cytochemical staining revealed that c-met was spontane-
ously overexpressed in SSc fibroblasts (Kawaguchi et al,
2002). We compared c-met expression levels between NS
and SSc fibroblasts using immunoblotting. The results
showed that both c-met a-subunit and b-subunit were
overexpressed in SSc fibroblasts compared with NS fibro-
blasts (Fig 3A). There is a possibility that this overexpression
of c-met is associated with the increased expression of
MMP-1 caused by HGF in SSc fibroblasts.
Additionally, immunoblotting analysis revealed that TGF-
b increased the expression of both c-met subunits in NS
fibroblasts in a time-dependent manner (Fig 3B). On the
other hand, SSc fibroblasts treated with the TGF-b1 anti-
sense oligonucleotide showed a marked reduction in the
protein expression of c-met as well as type I procollagen
(Fig 3C and S6). The sense oligonucleotide had no such
inhibitory effect. This antisense oligonucleotide did not af-
fect the protein expression in normal fibroblasts (data not
shown). These results indicate that the upregulated c-met
expression in SSc fibroblasts may be because of auctocrine
TGF-b signaling.
Overexpression of MMP-1 is involved in the reduction of
type I procollagen protein expression by HGF in SSc
ﬁbroblasts Next, we investigated whether MMP-1 is actu-
ally involved in the reduction of type I procollagen accu-
mulation by HGF in SSc fibroblasts using the MMP inhibitor,
GM1489 (Holleran et al, 1997) and ethylenediaminetetra-
acetic acid (EDTA) (Yamane et al, 2003). Pretreatment of the
cells with these reagents blocked the HGF-mediated down-
regulation of type I procollagen protein expression signifi-
cantly (Fig 4). This result suggests that MMP are involved in
the HGF-mediated downregulation of type I procollagen
protein expression in SSc.
Discussion
In this study, we showed that the hyper-reactivity of MMP-1
expression to HGF, which is probably a result of the over-
expression of c-met because of autocrine TGF-b signaling,
results in a downregulation of type I procollagen protein
expression in SSc fibroblasts.
As evidence for the contribution of autocrine TGF-b
signaling to the pathogenesis of SSc, the blockade of TGF-
b signaling with anti-TGF-b antibodies or a TGF-b1 anti-
sense oligonucleotide abolished the increase in mRNA ex-
pression as well as the upregulated transcriptional activity
of the human a2(I) collagen gene in SSc fibroblasts (Ihn et al,
Figure 2
Time- or concentration-dependent effects of hepatocyte growth
factor (HGF) on the expression of matrix metalloproteinase-1
(MMP-1), tissue inhibitor of metalloproteinase (TIMP)-1, or TIMP-2.
(A) For the examination of time dependency, cells were incubated in
serum-free medium for the indicated period in the presence or absence
of 10 ng per mL of HGF. Conditioned media were subjected to
immunoblotting with anti-MMP-1, TIMP-1, and TIMP-2 antibodies. (B)
Normal subjects (NS) and Systemic sclerosis (SSc) fibroblasts were
incubated in serum-free medium for 72 h in the presence or absence of
10 ng per mL of HGF prior to collection of the medium. Conditioned
media and cell lysates (normalized for protein concentrations as meas-
ured with the Bio-Rad reagent) were subjected to immunoblotting with
anti-MMP-1 antibody and anti-b-actin antibody, respectively. The rep-
resentative results for three NS and three SSc fibroblasts are shown.
MMP-1 protein levels quantitated by scanning densitometry and cor-
rected for the levels of b-actin in the same samples are shown relative
to those in NS (open bars) fibroblasts without HGF stimulation (100
arbitrary units). Data are expressed as the mean  SD of independent
experiments in each fibroblast.
326 JINNIN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
2001). Our results indicate that the upregulated c-met ex-
pression in SSc fibroblasts is also because of autocrine
TGF-b signaling. The overexpression of c-met may be a
biological feedback response to the fibrosis in SSc.
The overexpression of c-met has been reported in sev-
eral tumor cells including human colon cancer cells and
gastric carcinoma cells (Huang et al, 2001; Takeuchi et al,
2003). MMP induced by the overexpressed c-met may play
a part in the invasion or metastases of these tumors. There
has been no report, however, that discusses c-met overex-
pression or MMP-1 hyperreactivity to HGF in fibrotic dis-
eases other than SSc. These biological feedback responses
may occur under other fibrotic conditions. But as described
above, SSc fibroblasts with higher levels of c-met exhibit
reduced MMP-1 expression and increased collagen syn-
thesis although they are apparently more sensitive to the
effects of HGF. Furthermore, despite the anti-fibrotic prop-
erties of HGF, serum levels of HGF are markedly increased
in several fibrotic disorders including SSc (Tsubouchi et al,
1992; Takada et al, 1996; Hojo et al, 1997; Kawaguchi et al,
1999). These contradictions may be explained by the find-
ing that HGF levels in these fibrotic disorders were much
lower than those used in our study, suggesting that the
increase in serum HGF levels is insufficient to regulate
MMP-1 expression or collagen synthesis in SSc fibroblasts.
Indeed, Kawaguchi et al (2002) demonstrated an inhibitory
effect of higher concentrations (10–100 ng per mL) of HGF
on collagen production in skin fibroblasts, which is consist-
ent with our results.
Our study had some limitations because we could not
determine whether or not MMP-1 itself is involved in the
collagenolysis induced by HGF because of the lack of an
anti-MMP1-neutralizing antibody. There is some possibility
that excessive collagen accumulation caused by TGF-b
may positively influence c-met expression in SSc fibro-
blasts. Thus, further studies are needed to clarify the mech-
anisms of HGF-mediated collagenolysis or TGF-b-mediated
c-met overexpression in SSc fibroblasts.
Taken together, HGF seems to be a cytokine that medi-
ates tissue remodeling in the skin as well as in the liver. Our
results showed that HGF did not change the expression of
type I collagen in NS fibroblasts but decreased it in SSc
fibroblasts by increasing the expression of MMP-1. Thus,
our study indicates that HGF has little or no influence on the
amount of type I collagen in normal tissue, but that it de-
creases the deposition of type I collagen protein only under
fibrotic conditions in vivo.
Currently, several investigators have reported a thera-
peutic effect of cyclophosphamide, prednisolone, or met-
hotrexate therapy on the fibrosis of SSc (Pope et al, 2001;
Figure3
The expression levels of c-met in normal subjects (NS) and sys-
temic sclerosis (SSc) fibroblasts. (A) Whole-cell lysates obtained
from NS and SSc fibroblasts were electrophoresed through a 10%
polyacrylamide gel, transferred to a nitrocellulose membrane, and
probed with anti-c-met antibody. The same membrane was then
stripped and reprobed with anti-b-actin antibody as a loading control.
The results representative of three cases are shown. (B) For the ex-
amination of time dependency, NS fibroblasts were incubated in se-
rum-free medium for the indicated period in the presence or absence of
2 ng per mL of TGF-b. Cell lysates were subjected to immunoblotting
with anti-c-met antibody. The same membrane was then stripped and
reprobed with anti-b-actin antibody as a loading control. One repre-
sentative of independent experiments in five NS and five SSc fibro-
blasts is shown. The levels of a (open bars) and b subunits (closed bars)
quantitated by scanning densitometry and corrected for the levels of b-
actin in the same samples are shown relative to those in NS fibroblasts
without HGF stimulation (100 AU). Data are expressed as the
mean  SD of the results of five NS fibroblasts. (C) The effects of the
TGF-b1 antisense oligonucleotide on the expression levels of c-met
and type I procollagen were investigated by immunoblot analysis. SSc
fibroblasts were treated with the TGF-b1 sense oligonucleotide or the
TGF-b1 antisense oligonucleotide for 96 h. Conditioned media and cell
lysates (normalized for protein concentrations as measured by the Bio-
Rad reagent) were subjected to immunoblotting with anti-type I colla-
gen antibody and anti-c-met antibody, respectively. The same mem-
brane was then stripped and reprobed with anti-b-actin antibody as a
loading control. One representative of independent experiments in five
SSc fibroblasts is shown.
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Apras et al, 2003). Their approach, however, seems to be
initiated at the early stage of SSc, before the fibrosis begins
to develop. Furthermore, various significant adverse effects
of these treatments have to be considered (Haustein, 2002).
Our study raises the possibility of the clinical use of HGF
that its effect is limited to fibrotic lesions of SSc and that it
can improve dermal sclerosis in the chronic stage. Further
investigation of the effects of HGF on collagen metabolism
may contribute to the treatment of fibrosis in SSc.
Materials and Methods
Reagents Recombinant human HGF was obtained from R&D sys-
tems (Minneapolis, Minnesota). Anti-type I collagen UNLB was
purchased from SouthernBiotech (Birmingham, Alabama). Anti-
body for b-actin was from Sigma (St Louis, MissOuri). The antibody
for MMP-1 was from Chemicon (Temecula, California). The anti-
bodies against TIMP-1 and TIMP-2 were from Daiichi fine chemical
(Tokyo, Japan). Anti-c-met was from Santa Cruz Biotechnology
(Santa Cruz, California). GM1489 was from Calbiochem (La Jolla,
California). FuGENE 6 was obtained from Roche Diagnostics (In-
dianapolis, Indiana).
Cell cultures Human dermal fibroblasts were obtained by skin
biopsy from the affected areas (dorsal forearm) of five patients with
diffuse cutaneous SSc ando2 y of skin thickening (Ihn et al, 2001).
Control fibroblasts were obtained by skin biopsy from five healthy
donors. Institutional review board approval and written informed
consent were obtained according to the Declaration of Helsinki.
Control donors were matched with each SSc patient for age, sex,
and biopsy site, and control samples were processed in parallel.
Primary explant cultures were established in 75 cm2 culture flasks
in modified Eagle’s medium (MEM) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, and 50 mg per mL amphotericin.
Fibroblast cultures independently isolated from different individuals
were maintained as monolayers at 371C in 95% air, 5% CO2, and
studied between the third and sixth subpassages.
Treatment of dermal ﬁbroblasts with antisense TGF-b1
oligonucleotide We used a TGF-b1 19-mer antisense oligonuc-
leotide (GAGGGCGGCATGGGGAGG), which overlaps the promot-
er and transcriptional start site of the TGF-b1 gene. This same
sequence, which is specific for the TGF-b1 isoform, has been
found to be sufficient to block TGF-b1 transcription in vitro (Fa-
langa et al, 1998; Ihn et al, 2001) and in vivo (Brunet et al, 1995). A
sense oligonucleotide served as a control. Fibroblasts were grown
to confluence and the culture medium was removed, washed with
MEM to remove excess TGF-b1, and replaced with serum-free
MEM. Antisense or sense TGF-b1 oligonucleotide was added, and
immunoblotting was performed 96 h later.
Immunoblotting Dermal fibroblasts were cultured until they were
confluent. Cells were serum starved in MEM and 0.1% BSA for
24 h prior to the cytokine treatment. After incubation with the indi-
cated reagent, the condition medium was collected. Remaining
cells were washed with cold phosphate-buffered saline twice and
lysed in lysis buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Nonidet P-40, 50 mM sodium fluoride, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM sodium orthovanadate, 1 mg per mL
leupeptin, 1 mg per mL aprotinin, and 1 mg per mL pepstatin). Aliquots
of conditioned media (normalized for cell numbers) or cell lysates
(normalized for protein concentrations as measured by the Bio-Rad
reagent Bio-Rad Laboratories, Richmond, California) were subjected
to electrophoresis on sodium dodecyl sulfate-polyacrylamide gels
and transferred to nitrocellulose membranes. The membranes were
blocked for 1 h and incubated overnight at 41C with anti-type I
collagen, MMP-1, TIMP-1, TIMP-2, c-met, or b-actin antibody. The
membranes were washed in Tris-buffered saline and 0.1% Tween 20,
incubated with secondary antibodies, and washed again. The de-
tection was performed using the Enhanced Chemiluminescence De-
tection system (Amersham, Arlington Heights, Illinois).
RNA preparation and northern blot analysis Total RNA was ex-
tracted using an acid guanidinium thiocyanate–phenol–chloroform
method and analyzed by Northern blotting, as described previously
(Ihn et al, 1996, 1997). RNA was subjected to electrophoresis
on 1% agarose/formaldehyde gels and blotted onto nylon filters
(Roche Diagnostics). The filters were UV cross-linked, prehybrid-
ized, and sequentially hybridized with cDNA probes. The following
cDNA probes were used: human a2(I) collagen PstI–HindIII frag-
ment, MMP-1 XhoI fragment, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) NotI–HindIII fragment. The membranes
were then washed and exposed to X-ray film.
MMP-1 activity assay The active MMP-1 level was determined
using the MMP-1 Biotrak activity assay system (Amersham), ac-
cording to the manufacturer’s directions (Verheijen et al, 1997).
Briefly, anti-MMP-1 antibodies were precoated onto microtiter
wells. Cultured medium was added to each well, and incubation
was conducted at 41C overnight. The wells were washed and the
absorbance at 405 nm was measured before and after the incu-
bation with a specific chromogenic peptide substrate for 1.5 h. The
concentration of active MMP-1 in each sample was determined by
interpolation from a standard curve.
Plasmids Generation of a 3500 COL1A2/CAT construct consist-
ing of the full-length human a2(I) collagen gene fragment (þ 58 to
3500 bp relative to the transcription start site) linked to the chlo-
ramphenicol acetyltransferase (CAT) reporter gene was previously
described (Ihn et al, 1996). The full-length 4372 bp clone of the
human MMP-1 promoter containing fragments of promoter DNA
linked to the luciferase reporter was kindly provided by Dr Con-
stance E. Brinckerhoff (Rutter et al, 1997). Plasmids used in the
Figure 4
Effects of GM1489 and ethylenediaminetetraacetic acid (EDTA) on
the hepatocyte growth factor (HGF)-reduced type I procollagen
protein in Systemic sclerosis (SSc) fibroblasts. SSc fibroblasts were
serum starved for 24 h and pretreated with 20 mM GM1489 or 1 mM
EDTA, for 1 h prior to the addition of 10 ng per mL of HGF for 72 h.
Conditioned media and cell lysates (normalized for protein concentra-
tions as measured by the Bio-Rad reagent) were subjected to immuno-
blotting with anti-type I collagen antibody and anti-b-actin antibody,
respectively. One representative of independent experiments in five
SSc fibroblasts is shown. Type I procollagen protein levels quantitated
by scanning densitometry and corrected for the levels of b-actin in the
same samples are shown relative to those in SSc fibroblasts without
HGF stimulation (100 AU). Data are expressed as the mean  SD of the
results of five SSc fibroblasts.
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transient transfection assays were purified twice on cesium chlo-
ride gradients, as described previously (Ihn et al, 1997). At least
two different plasmid preparations were used for each experiment.
The transient transfection Fibroblasts were grown to 50% con-
fluence in 100-mm dishes in MEM with 10% fetal calf serum. The
MEM was replaced with serum-free medium, and fibroblasts were
transfected with the promoter constructs, using FuGENE6 as de-
scribed previously (Ihn et al, 2002). In order to normalize for minor
variations in transfection efficiency, 1 mg pSV-b-galactosidase vec-
tor (Promega, Madison, Wisconsin) was included in all trans-
fections. After 24 h incubation, cells were incubated for 24 h
additionally in the absence or presence of 10 ng per mL of HGF.
Subsequently, cells were harvested in 0.25 M Tris-HCl (pH 8) and
fractured by freeze-thawing for the CAT assay or luciferase assay.
Each experiment was performed in duplicate.
Statistical analysis Statistical analysis was carried out with the
Mann–Whitney test for comparison of means. p-values less than
0.05 were considered to be significant.
We would like to thank Dr Constance E. Brinckerhoff for kindly providing
the full-length 4372 bp clone of the human collagenase (MMP-1)
promoter. This study is supported in part by a grant for scientific
research from the Japanese Ministry of Education, and by project
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Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23601/JID23601sm.htm
Figure S1 NS and SSc ﬁbroblasts were transiently transfected with a
full-length a2(I) collagen promoter.
Figure S2 For the examination of the dose-dependency of the HGF
effect, cells were incubated in serum-free medium for 72 hours in the
presence or absence of HGF at the indicated doses prior to collection of
the medium.
Figure S3 Cultured ﬁbroblasts were incubated in the presence or ab-
sence of 10 ng per mL of HGF under the same conditions for the in-
dicated time courses, and the northern blot analysis of MMP-1 mRNA
expression was performed in NS and SSc ﬁbroblasts.
Figure S4 NS and SSc ﬁbroblasts were transiently transfected with a
full-length MMP-1 promoter. After incubation overnight, cells were incu-
bated in the absence or presence of 10 ng per mL of HGF for an ad-
ditional 24 hours.
Figure S5 NS and SSc ﬁbroblasts were incubated in serum-free me-
dium for 72 hours in the presence or absence of 10 ng per mL of HGF
prior to collection of the medium.
Figure S6 The effects of the TGF-b1 antisense oligonucleotide on the
expression levels of c-met and type I procollagen were investigated by
immunoblot analysis.
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